Helen Heslop
#103,274
Most Influential Person Now
New Zealand physician-scientist
Helen Heslop's AcademicInfluence.com Rankings
Helen Heslopphilosophy Degrees
Philosophy
#5065
World Rank
#7782
Historical Rank
Logic
#2408
World Rank
#3394
Historical Rank
Download Badge
Philosophy
Helen Heslop's Degrees
- Masters Medicine University of New Zealand
- Doctorate Medicine University of New Zealand
Why Is Helen Heslop Influential?
(Suggest an Edit or Addition)According to Wikipedia, Helen Elisabeth Heslop is a physician-scientist from New Zealand whose clinical interests are in hematopoietic stem cell transplants. Heslop’s research focuses on immunotherapy to treat viral infections, post transplant and hematologic malignancies. She is a professor in the Department of Medicine and Pediatrics at Baylor College of Medicine and the director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital. She is also the Dan L. Duncan Chair and the associate director of clinical research at the Dan L. Duncan Cancer Center.
Helen Heslop's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Inducible apoptosis as a safety switch for adoptive cell therapy. (2011) (1225)
- Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation (1995) (1192)
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma (2008) (1117)
- Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. (1998) (992)
- Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. (2011) (963)
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. (2011) (894)
- Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes (1996) (853)
- Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. (2015) (719)
- Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. (2010) (671)
- An inducible caspase 9 safety switch for T-cell therapy. (2005) (599)
- Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals (2006) (544)
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial (2017) (487)
- Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. (2014) (472)
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety (2010) (457)
- Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. (2013) (454)
- T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. (2009) (442)
- Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients (1993) (435)
- Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. (2013) (431)
- A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. (2005) (428)
- Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. (2014) (410)
- Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease (2004) (396)
- TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy (2013) (372)
- Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. (2005) (359)
- Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT (2014) (334)
- Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients (1998) (333)
- CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. (2017) (329)
- HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors (2010) (328)
- Post-transplant lymphoproliferative disorders. (2005) (320)
- Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. (2002) (314)
- Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. (2009) (313)
- Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. (1994) (307)
- Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. (1998) (303)
- Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. (2007) (288)
- TUMOUR NECROSIS FACTOR AS AN AUTOCRINE TUMOUR GROWTH FACTOR FOR CHRONIC B-CELL MALIGNANCIES (1988) (283)
- Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. (2017) (282)
- How I treat EBV lymphoproliferation. (2009) (279)
- CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. (2000) (278)
- T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. (2006) (265)
- An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. (2001) (262)
- Adenovirus infection after pediatric bone marrow transplantation (1999) (261)
- Donor T cells to treat EBV-associated lymphoma. (1994) (261)
- Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). (2006) (257)
- Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. (2017) (253)
- Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative disease (1995) (247)
- Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. (2015) (245)
- Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. (2006) (244)
- Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. (2009) (240)
- Quantitative EBV Viral Loads and Immunosuppression Alterations can Decrease PTLD Incidence in Pediatric Liver Transplant Recipients (2005) (236)
- Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. (2007) (234)
- Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. (2011) (233)
- Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma (2013) (227)
- T-cell therapy in the treatment of post-transplant lymphoproliferative disease (2012) (225)
- Prompt versus preemptive intervention for EBV lymphoproliferative disease. (2004) (225)
- Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. (2016) (222)
- Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections (2012) (218)
- Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. (2007) (203)
- Adoptive T cell therapy of cancer. (2010) (203)
- Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma (2010) (202)
- Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. (2017) (202)
- Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor (2008) (200)
- Adoptive cellular immunotherapy for EBV lymphoproliferative diseases (1997) (194)
- Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. (2013) (193)
- Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. (2003) (186)
- Outcomes of transplantation with matched-sibling and unrelateddonor bone marrow in children with leukaemia (1997) (186)
- Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential (1991) (183)
- Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. (2015) (175)
- Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines (2016) (174)
- Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. (2009) (174)
- Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity (2014) (170)
- Regression of experimental medulloblastoma following transfer of HER2-specific T cells. (2007) (167)
- Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. (2003) (166)
- Evidence for the Presentation of Major Histocompatibility Complex Class I–restricted Epstein-Barr Virus Nuclear Antigen 1 Peptides to CD8+ T Lymphocytes (2004) (164)
- Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. (2007) (161)
- Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. (2010) (160)
- T cells for viral infections after allogeneic hematopoietic stem cell transplant. (2016) (159)
- Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells (1994) (151)
- Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. (2002) (151)
- Accelerated Production of Antigen-specific T Cells for Preclinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex) (2010) (150)
- Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. (2014) (144)
- In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. (2018) (143)
- Reversal of tumor immune inhibition using a chimeric cytokine receptor. (2014) (140)
- Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy (2007) (138)
- Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. (2020) (137)
- Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis (2008) (136)
- Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. (1989) (134)
- Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. (1995) (133)
- Efficient infection of primitive hematopoietic stem cells by modified adenovirus (2001) (130)
- Fine-tuning the CAR spacer improves T-cell potency (2016) (126)
- Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. (1995) (125)
- Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath) (2005) (123)
- Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. (2010) (120)
- In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. (1989) (118)
- Generation of EBV-Specific CD4+ Cytotoxic T Cells from Virus Naive Individuals1 (2002) (117)
- Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. (2006) (117)
- CARs on track in the clinic. (2011) (116)
- Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. (2018) (115)
- Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. (2009) (113)
- Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. (2018) (113)
- CAR-T Cell Therapy for Lymphoma. (2016) (112)
- Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. (2008) (110)
- Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. (2005) (109)
- The Generation and Characterization of LMP2-Specific CTLs for Use as Adoptive Transfer From Patients With Relapsed EBV-Positive Hodgkin Disease (2004) (107)
- Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B cell non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. (2019) (107)
- Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. (1989) (106)
- Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. (2016) (102)
- CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo (2015) (102)
- Adoptive cellular immunotherapy for EBV lymphoproliferative disease. (1997) (100)
- Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. (2001) (99)
- Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. (2014) (98)
- Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. (2001) (98)
- Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma. (2013) (98)
- Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. (2009) (95)
- Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). (2008) (93)
- Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. (2004) (89)
- High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. (2011) (88)
- Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein‐Barr virus–positive Hodgkin's lymphoma (2001) (88)
- A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. (1989) (88)
- Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. (1994) (86)
- Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. (2006) (86)
- Cellular Immunity to Epstein‐Barr Virus in Liver Transplant Recipients Treated with Rituximab for Post‐Transplant Lymphoproliferative Disease (2005) (84)
- Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. (2011) (83)
- A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. (2007) (82)
- Immunotherapy of hematologic malignancy. (2003) (82)
- A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells (2004) (81)
- Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders (1990) (81)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. (2019) (80)
- Adoptive cellular immunotherapy for viral diseases (2008) (80)
- Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation (2007) (80)
- Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. (2010) (80)
- Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. (2002) (79)
- Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. (2006) (79)
- An Approach to the Preservation of Digital Records (2002) (79)
- Adoptive Immunotherapy for EBV-associated Malignancies (2005) (76)
- Psychological effects of bone marrow transplantation on children and adolescents: preliminary report of a longitudinal study. (1995) (76)
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) (2019) (74)
- Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma (2020) (73)
- Human gene marker/therapy clinical protocols. (1996) (73)
- Immunotherapy for Epstein-Barr virus-associated cancers. (1998) (72)
- Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. (2013) (72)
- Posttransplant lymphoproliferative disease following liver transplantation (2011) (71)
- Large-Scale Expansion of Dendritic Cell-Primed Polyclonal Human Cytotoxic T-Lymphocyte Lines Using Lymphoblastoid Cell Lines for Adoptive Immunotherapy (2003) (71)
- Adoptive immunotherapy for posttransplantation viral infections. (2004) (71)
- Definitions of histocompatibility typing terms. (2011) (70)
- Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. (2003) (70)
- The clinical use of LMP2-specific cytotoxic T lymphocytes for the treatment of relapsed EBV +ve Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL) (2006) (70)
- Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. (2009) (69)
- Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation (2007) (69)
- Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. (2012) (68)
- Interleukin 15 Provides Relief to CTLs from Regulatory T Cell–Mediated Inhibition: Implications for Adoptive T Cell–Based Therapies for Lymphoma (2012) (67)
- Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4 (2011) (67)
- Immunotherapy for Post‐Transplant Lymphoproliferative Disease (2002) (66)
- Optimizing the production of suspension cells using the G-Rex “M” series (2014) (65)
- Treatment of Epstein-Barr virus-associated malignancies with specific T cells. (2002) (64)
- Use of cytokine polymorphisms and Epstein–Barr virus viral load to predict development of post‐transplant lymphoproliferative disorder in paediatric liver transplant recipients (2006) (64)
- An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell Therapies (2010) (63)
- Human Papillomavirus Type 16 E6/E7-specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-associated Malignancies (2013) (63)
- Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation. (1994) (62)
- Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma (2012) (62)
- Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. (2002) (59)
- Immunotherapy for Epstein-Barr virus-associated cancers in children. (2003) (59)
- Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. (2005) (58)
- Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation (2007) (57)
- Antiviral T‐cell therapy (2014) (56)
- Engineered off-the-shelf therapeutic T cells resist host immune rejection (2020) (56)
- Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma1 (2005) (56)
- New ISSCR guidelines: clinical translation of stem cell research (2016) (56)
- Adoptive T‐cell transfer in cancer immunotherapy (2006) (56)
- Guillain–Barré syndrome after allogeneic hematopoietic stem cell transplantation (2002) (55)
- Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high‐risk for EBV infection (2006) (55)
- Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient (2002) (54)
- Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. (2001) (52)
- Human gene marker/therapy clinical protocols. (1999) (51)
- Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia. (1989) (51)
- Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial. (2015) (50)
- Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. (2004) (50)
- Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? (2012) (50)
- Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. (1998) (50)
- Impending challenges in the hematopoietic stem cell transplantation physician workforce. (2009) (50)
- Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60–78 years of age (2011) (49)
- Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma (2010) (47)
- Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. (2011) (47)
- Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab (2005) (47)
- T-cell immunotherapy: looking forward. (2014) (47)
- Policy: Global standards for stem-cell research (2016) (46)
- Epstein–Barr virus lymphoproliferative disease after hematopoietic stem cell transplant (2014) (46)
- Survivin-specific T cell receptor targets tumor but not T cells. (2015) (45)
- Adoptive T-Cell Therapy for EBV-Associated Post-Transplant Lymphoproliferative Disease (2003) (45)
- Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. (2008) (45)
- Gene Marking and Autologous Bone Marrow Transplantation a (1994) (44)
- Correction of Duncan's syndrome by allogeneic bone marrow transplantation (1993) (44)
- Assessing the Safety of Cytotoxic T Lymphocytes Transduced With a Dominant Negative Transforming Growth Factor-β Receptor (2006) (43)
- Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies (2019) (43)
- Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. (2002) (43)
- Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. (2021) (42)
- Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation (1991) (42)
- Ex vivo gene transfer for improved adoptive immunotherapy of cancer. (2011) (42)
- Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. (1999) (42)
- Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. (2007) (42)
- CD30‐CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR THERAPY OF HODGKIN LYMPHOMA (HL) (2018) (41)
- Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. (1996) (41)
- Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. (2004) (41)
- Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma (2005) (41)
- EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. (2018) (40)
- Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. (2012) (40)
- Cytotoxic T lymphocytes as immune‐therapy in haematological practice (2008) (40)
- Requirements for the adoptive transfer of antibody responses to a priming antigen in man. (1990) (36)
- Exploiting Cytokine Secretion to Rapidly Produce Multivirus-specific T Cells for Adoptive Immunotherapy (2008) (36)
- Complementation of Antigen-presenting Cells to Generate T Lymphocytes With Broad Target Specificity (2014) (36)
- EBV Specific CTL: A Model for Immune Therapy (1998) (35)
- Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. (2003) (34)
- Abstract LB-147: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas (2019) (34)
- The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. (2010) (34)
- Transfusion‐related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemia (2004) (33)
- Immunotherapy for Hodgkin's disease. (2002) (33)
- Immunotherapy targeting EBV-expressing lymphoproliferative diseases. (2008) (33)
- Malignant plasma cells are sensitive to LAK cell lysis: pre‐clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma (1990) (32)
- Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma. (2017) (31)
- Antigen-specific T cell therapies for cancer. (2015) (31)
- Transfer of EBV‐specific CTL to prevent EBV lymphoma post bone marrow transplant (1999) (31)
- T-cell therapy for viral infections. (2013) (31)
- The immunogenicity of virus-derived 2A sequences in immunocompetent individuals (2013) (30)
- Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. (2016) (30)
- Immunotherapy of leukemia. (1992) (30)
- Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution (2010) (30)
- Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease (2013) (30)
- T lymphocytes targeting native receptors (2014) (30)
- "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients. (2019) (29)
- Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation. (2005) (29)
- Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. (1996) (29)
- Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies (1999) (29)
- An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell Therapies. (2009) (29)
- The Use of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus Induced Lymphoma in Transplant Recipients (2000) (28)
- T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor–Expressing T Cells (2019) (28)
- Definitions of histocompatibility typing terms: Harmonization of Histocompatibility Typing Terms Working Group. (2011) (28)
- T‐Cell Immunotherapy for Adenoviral Infections of Stem‐Cell Transplant Recipients (2005) (28)
- Crosstalk between Medulloblastoma Cells and Endothelium Triggers a Strong Chemotactic Signal Recruiting T Lymphocytes to the Tumor Microenvironment (2011) (28)
- Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. (2000) (27)
- Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. (1994) (27)
- High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. (2018) (27)
- Epstein-Barr infection after bone marrow transplantation. (1994) (27)
- Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. (1997) (26)
- Late-Onset Severe Chronic Active EBV in a Patient for Five Years with Mutations in STXBP2 (MUNC18-2) and PRF1 (Perforin 1) (2015) (26)
- Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refractory NHL. (2002) (26)
- Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. (2014) (26)
- Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy (1989) (26)
- Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1 (1995) (25)
- In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation. (1988) (25)
- A Single Institution Experience With Pediatric Nasopharyngeal Carcinoma: High Incidence of Toxicity Associated With Platinum-based Chemotherapy Plus IMRT (2007) (25)
- Chimeric T Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas (2015) (25)
- Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells. (1991) (25)
- In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation (2006) (24)
- Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. (2015) (24)
- T‐cell receptor sequencing demonstrates persistence of virus‐specific T cells after antiviral immunotherapy (2019) (24)
- Use of gene marking in bone marrow transplantation. (1996) (24)
- Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. (1998) (24)
- Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies (2021) (23)
- Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. (2015) (23)
- Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. (2003) (23)
- Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. (2000) (22)
- Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. (2004) (22)
- Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus. (1990) (22)
- Recent advances in T‐cell immunotherapy for haematological malignancies (2017) (22)
- Genetic modification of T cells. (2011) (21)
- Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant. (2020) (21)
- Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia (2020) (20)
- Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling (2016) (20)
- Current status of genetic modification of T cells for cancer treatment. (2005) (20)
- Survival outcomes of allogeneic hematopoietic cell transplants with EBV‐positive or EBV‐negative post‐transplant lymphoproliferative disorder, A CIBMTR study (2019) (19)
- The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. (2018) (19)
- A yeast artificial chromosome (YAC) contig encompassing the critical region of the X-linked lymphoproliferative disease (XLP) locus. (1997) (19)
- Gene transfer into human hemopoietic progenitor cells. (1995) (19)
- Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. (2008) (19)
- Safer CARS. (2010) (19)
- Complement‐Fixing CD45 Monoclonal Antibodies to Facilitate Stem Cell Transplantation in Mouse and Man (2003) (19)
- Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen (2003) (19)
- Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. (2006) (18)
- The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma (2020) (18)
- Immunotherapy to reconstitute immunity to DNA viruses. (2002) (18)
- Blood and marrow transplant clinical trials network state of the Science Symposium 2014. (2015) (18)
- Graft-versus-host reactions and bone-marrow transplantation. (1991) (18)
- Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR (2019) (18)
- XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. (1994) (18)
- Selective Elimination of a Chemoresistant Side-Population of B-CLL Cells by Cytotoxic T Lymphocytes in Subjects Receiving an Autologous hCD40L/IL-2 Tumor Vaccine (2009) (18)
- Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. (2017) (17)
- Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. (2003) (17)
- CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors (2005) (16)
- Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML) (2006) (16)
- Plasma Markers of B-Cell Activation and Clonality in Pediatric Liver and Hematopoietic Stem Cell Transplant Recipients (2013) (16)
- T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects (2021) (16)
- HAEMOPOIETIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS (1999) (16)
- Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation (2001) (16)
- Twin pregnancy and parturition in a patient with the Bernard Soulier syndrome. (2009) (16)
- Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. (2011) (15)
- T cell therapies. (2006) (14)
- Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. (1993) (14)
- Is retroviral gene marking too dangerous to use? (2003) (14)
- T-Cell Immunotherapy: Looking Forward: T Cell Immunotherapy: Optimizing Trial Design Bethesda, Maryland 10-11 September 2013. (2014) (14)
- Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT) (2010) (14)
- Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH (2020) (14)
- Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells. (1998) (14)
- Preparing for growth: current capacity and challenges in hematopoietic stem cell transplantation programs. (2010) (14)
- Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. (2018) (14)
- Measuring gene–transfer efficiency (1996) (14)
- IL‐2 infusion abrogates humoral immune responses in humans (1992) (13)
- Multi-Virus-Specific T-Cell Therapy For Patients After Hematopoietic Stem Cell and Cord Blood Transplantation (2013) (13)
- Gene-marking and haemopoietic stem-cell transplantation. (1995) (13)
- Possible mechanism of action of interferon alpha in chronic B‐cell malignancies (1991) (13)
- Energy expenditure in children undergoing hematopoietic stem cell transplantation (2002) (13)
- Gene-Marked Autologous Hematopoietic Stem Cell Transplantation of Autoimmune Disease (2004) (13)
- Pediatric Blood and Marrow Transplantation: State of the Science (2008) (13)
- Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. (2018) (12)
- Gene transfer and bone marrow transplantation. (1994) (12)
- Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor-Associated Antigens (2016) (12)
- Clinical Responses In Patients Infused With T Lymphocytes Redirected To Target κ-Light Immunoglobulin Chain (2013) (12)
- Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens. (2008) (12)
- T cell therapy in allogeneic stem cell transplantation. (2008) (12)
- Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging. (2010) (12)
- Effects of tumour necrosis factor and alpha interferon on chronic B cell malignancies. (1988) (12)
- Gene and Cell Transfer for Specific Immunotherapy (1998) (11)
- Gene marking after bone marrow transplantation. (1994) (11)
- Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas. (2021) (11)
- CARs on Track in the Clinic: Workshop of the Blood and Marrow Transplant Clinical Trials Network Subcommittee on Cell and Gene Therapy Washington DC, 18 May 2010. (2011) (11)
- Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. (2016) (11)
- ALLOGENEIC RED BLOOD CELLS FAIL TO INDUCE HAEMAGGLUTINATING ANTIBODIES OR CELLULAR ALLOIMMUNITY IN RATS AND ARE IMMUNOSUPPRESSIVE (1979) (11)
- Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences. (2008) (11)
- Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM‐CSF (1989) (11)
- Gene-Marking studies of hematopoietic cells (2001) (11)
- Use of marker genes to investigate the mechanism of relapse and the effect of bone marrow purging in autologous transplantation for stage D neuroblastoma. (1993) (10)
- Taking T-Cell Oncotherapy Off-the-Shelf. (2021) (10)
- Forecasting Cytokine Storms with New Predictive Biomarkers. (2016) (10)
- Graft versus leukaemia effects after marrow transplantation in man. (1991) (10)
- Hyponatraemic-hypertensive syndrome due to unilateral renal ischaemia in women who smoke heavily. (1985) (10)
- Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation. (1996) (10)
- Autologous HER2 CMV bispecific CAR T cells for progressive glioblastoma: Results from a phase I clinical trial. (2015) (10)
- Genetic modification of T cells with a novel bispecific chimeric antigen receptor to enhance the control of high-grade glioma (HGG). (2014) (10)
- Abstract 3500: T cells redirected against HER2 for the adoptive immunotherapy for HER2-positive osteosarcoma (2012) (9)
- Children with acute leukemia: A comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation (2010) (9)
- Adoptive T-Cell Therapy for Epstein-Barr Virus-Positive Hodgkin’s Disease (2003) (9)
- Viral lymphomagenesis (2006) (9)
- Human gene marker/therapy clinical protocols. (1997) (9)
- Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-ß to Patients with EBV-Associated Lymphomas (2010) (9)
- Immunotherapy: opportunities, risks and future perspectives. (2014) (9)
- Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. (2019) (9)
- HIGH GRADE GLIOMAS (2012) (8)
- Donor-Derived Multiple Leukemia Antigen Specific T-cell Therapy to Prevent Relapse Post-Transplant in Patients with ALL. (2022) (8)
- Immunotherapy for Epstein-Barr Virus-Related Lymphomas (2009) (8)
- Combining drugs and biologics to treat nasopharyngeal cancer. (2014) (8)
- Phase I Study to Improve Virus-Specific Immune Reconstitution After Cord Blood Transplantation Using Cord Blood-Derived Virus-Specific Cytotoxic T Lymphocytes (2011) (8)
- Reconstitution of the T cell receptor αβ repertoire in recipients of allogeneic BMT (1992) (8)
- Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma (2021) (8)
- Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study (2021) (7)
- T-cell-based therapies for malignancy and infection in childhood. (2010) (7)
- Clinical Responses in Patients Infused with T Lymphocytes Redirected to Target Kappa-Light Immunoglobulin Chain (2014) (7)
- Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma (2013) (7)
- Erratum: Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma (Journal of Immunology (2005) 175 (4137-4147)) (2005) (7)
- Gene therapy for paediatric leukaemia (2001) (7)
- U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH RECOMBINANT DNA ADVISORY COMMITTEE Minutes of Meeting (2006) (6)
- Interleukin-2 infusion after autologous bone marrow transplantation enhances hemopoietic regeneration. (1991) (6)
- Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial) (2021) (6)
- New approaches in alternative donor transplantation. (2013) (6)
- Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy (2013) (6)
- Allogeneic Stem Cell Transplantation in a Pediatric Patient with Whim Syndrome (2015) (6)
- Checkpoint inhibition and cellular immunotherapy in lymphoma. (2016) (6)
- Sensitizing Burkitt lymphoma to EBV-CTLs. (2020) (6)
- Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor Associated Antigens (2015) (6)
- Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma (2021) (6)
- Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression (2009) (6)
- CASPALLO: Phase I Clinical Trial of Allodepleted T Cells Transduced with Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation (2010) (6)
- A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma (2020) (6)
- Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study (2021) (6)
- CD5 CAR T-Cells for Treatment of Patients with Relapsed/Refractory CD5 Expressing T-Cell Lymphoma Demonstrates Safety and Anti-Tumor Activity (2020) (6)
- CAR‐T cell therapy for non‐Hodgkin lymphomas: A new treatment paradigm (2019) (6)
- Aggressive peripheral CD70‐positive t‐cell lymphoma associated with severe chronic active EBV infection (2012) (5)
- Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma (2017) (5)
- Genetically engineered T-cells for adoptive immunotherapy. (2002) (5)
- Evaluation of Aprepitant for Treatment of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Undergoing Autologous Stem Cell Transplantation. (2004) (5)
- Delayed Induction of Proto-Oncogene Expression in B-CLL Cells by Tumor Necrosis Factor. (1990) (5)
- Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium. (2018) (5)
- Exhausting alloreactivity of donor-derived CAR T cells (2017) (5)
- Administering Leukemia-Directed Donor Lymphocytes to Patients with AML or MDS to Prevent or Treat Post-Allogeneic HSCT Relapse (2019) (5)
- Equal-opportunity treatment of EBV-PTLD. (2012) (5)
- Improving Immune Reconstitution After Cord Blood Transplantation Using Ex Vivo Expanded Virus-Specific T Cells: A Phase I Clinical Study (2012) (5)
- Safety of Multiple Doses of CAR T Cells (2015) (5)
- Immune therapy for EBV infections after hemopoietic stem-cell transplant. (2002) (5)
- A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS). (2020) (5)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy (2021) (5)
- Fall of the mutants: T cells targeting BCR-ABL. (2017) (5)
- High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia (2021) (5)
- Hepatic arterial resistance index--an indicator of diffuse liver disease in children treated with bone marrow transplantation. (1997) (5)
- Naïve T-cell-derived CTL recognize atypical epitopes of CMVpp65 with higher avidity than CMV-seropositive donor-derived CTL - a basis for treatment of post-transplant viral infection by adoptive transfer of T-Cells from virus-naïve donors (2013) (4)
- Cytokine gene transfer in the therapy of malignancy. (1994) (4)
- Homeostatic action of interleukin-4 on endogenous and recombinant interleukin-2-induced activated killer cell function. (1991) (4)
- TREATMENT OF SOLID ORGAN TRANSPLANT RECIPIENTS WITH AUTOLOGOUS EPSTEIN BARR VIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES (CTL). Running title: T cell therapy for PTLD in Solid organ transplant recipients (2006) (4)
- White Paper on Measurement of Quality Outcomes (2006) (4)
- Current Allogeneic HSCT for Pediatric ALL: Success, Failure and Future Perspectives- a Single Center Experience 2008-2016. (2018) (4)
- Childhood Leukemias: Adoptive cellular immunotherapy (2006) (4)
- Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs (2022) (4)
- Transfer of marker genes into hemopoietic progenitor cells. (1996) (4)
- Chimeric T-Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas (HL & NHL) (2016) (4)
- 5: Long-Term Follow-Up of Administration of Donor-Derived EBV-Specific CTLs to Prevent and Treat EBV Lymphoma After Hemopoietic Stem Cell Transplant (2008) (4)
- A backpack revs up T-cell activity (2018) (4)
- Gene transfer for the therapy of hematologic malignancy (1995) (4)
- Genetic engineering of T-cell receptors: TCR takes to titin. (2013) (4)
- Pharmacotherapy versus T lymphocytes for CMV. (2013) (4)
- BMT CTN State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. (2021) (4)
- Direct comparison of in vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with b cell non-hodgkin lymphoma (B-NHL): Reversal of toxicity from tonic signaling (2017) (4)
- Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T-cells for T-cell malignancies. (2022) (4)
- Genetic errors of immunity distinguish pediatric non-malignant lymphoproliferative disorders. (2021) (4)
- Priorities for Improving Outcomes for Non-Malignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. (2020) (3)
- 244: Treatment of Epstein Barr Virus Positive Nasopharyngeal Carcinoma with Adoptively Transferred Cytotoxic T Lymphocytes (2008) (3)
- Administration of LMP-specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive lymphoma post allogeneic stem cell transplant (2015) (3)
- Harmonizing Immune Effector Toxicity Reporting. (2019) (3)
- Preventing Epstein-Barr virus lymphoproliferative disease after bone marrow transplantation. (2001) (3)
- The t(9;22) translocation in Philadelphia-positive essential thrombocythaemia does not involve the T lymphocyte lineage. (1990) (3)
- Calcineurin Inhibitor-Free Graft-Versus-Host Disease (GVHD) Prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: Results of the BMT CTN 1301 Progress II Trial (2021) (3)
- CRISPR-Edited Immune Effectors: The End of the Beginning. (2020) (3)
- Safety and Clinical Efficacy of Rapidly-Generated Virus-Specific T Cells with Activity Against Adv, EBV, CMV, HHV6 and BK Virus Administered after Allogeneic Hematopoietic Stem Cell Transplant (2013) (3)
- Virus-specific T cells for malignancies - then, now and where to? (2020) (3)
- Genetic Modification of Multi Leukemia Antigen-Specific Cytotoxic T Lymphocytes (CTL) to Enhance In Vivo Safety and Persistency (2011) (3)
- Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against Adv, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant (2018) (3)
- A method for preparing leucocyte depleted erythrocytes from rat blood. (1978) (3)
- T Cell Immunotherapy: Optimizing Trial Design (2014) (3)
- Late-Onset Severe Chronic Active EBV in a Patient for Five Years with Mutations in STXBP2 (MUNC18-2) and PRF1 (Perforin 1) (2015) (3)
- The “Side-Population” of Human Lymphoma Cells have Increased Chemo-Resistance, Stem-Cell Like Properties and are Potential Targets for Immunotherapy (2008) (3)
- Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Children’s Hospital experience (2021) (3)
- Getting Personal with Melanoma (2011) (3)
- Stereotactic body radiation therapy and in situ oncolytic virus therapy followed by immunotherapy in metastatic non-small cell lung cancer. (2021) (3)
- Equal opportunity CAR T cells. (2017) (3)
- Haploidentical Stem Cell Transplants in Children With Acute Lymphoblastic Leukemia in First or Second Remission (2011) (3)
- Acute GvHD Incidence and Outcome: Single Center Experience (2017) (3)
- Robust T-cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy (2013) (3)
- 37. Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T Cells Demonstrate Reactivity Against Emerging Variant Strains (2021) (3)
- Upper airway obstruction and pulmonary abnormalities due to lymphoproliferative disease following bone marrow transplantation in children (1998) (3)
- A Novel Approach to Manufacture CAR-T Cells for Clinical Applications (2013) (3)
- Generation and administration of autologous T cells transduced with a 3rd generation GD2 chimeric antigen receptor for patients with relapsed or refractory neuroblastoma (2014) (3)
- Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive Immunotherapy of EBV-associated malignancies Running title: Generation of LMP1-specific CTL Scientific Section Heading: Immunotherapy (2002) (3)
- The Use of Autologous LMP2-Specific Cytotoxic T Lymphocytes (CTL) for the Treatment of Relapsed EBV-Positive Hodgkin Disease and Non-Hodgkin Lymphoma. (2005) (3)
- LossoftheAmino-Terminal Helix-Loop-Helix Domainofthevav Proto-Oncogene Activates ItsTransforming Potential (1991) (2)
- 795. The Use of Autologous LMP2-Specific Cytotoxic T Lymphocytes for the Treatment of Relapsed EBV +ve Hodgkin Disease and Non-Hodgkin Lymphoma (2005) (2)
- Safety and Efficacy of Adoptively Transferred Donor-Derived Tumor-Directed T Cells with Relapsed AML Post-Allogeneic HSCT (2017) (2)
- Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells. (2019) (2)
- Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. (2022) (2)
- Immunotherapy for malignancies and viral infections (2000) (2)
- Monoculture-Derived T Lymphocytes Providing Multiple Virus Specificity and Anti-Leukemia Activity for Recipients of Hematopietic Stem Cells or Umbilical Cord Blood Transplants (2008) (2)
- TNF and chronic B lymphoproliferative disorders. (1993) (2)
- Allogeneic Hematopoietic Cell Transplants in Patients with Myelofibrosis Age 60 and Older (2008) (2)
- Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma (2018) (2)
- Improving T Cell Therapy for Relapsed EBV-Negative Hodgkin's Lymphoma by Targeting Upregulated MAGE-A4 (2011) (2)
- Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies. (2020) (2)
- Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant (2015) (2)
- Cellular immunotherapy of EBV-associated lymphomas (1998) (2)
- Naïve T Cell-Derived CTL Recognize Atypical Epitopes of CMVpp65 with Higher Avidity Than CMV-Seropositive Donor-Derived CTL – a Basis for Treatment of Post-Transplant Viral Infection by Adoptive Transfer of T Cells From Virus-naïve Donors (2011) (2)
- A PHASE 1 Perspective: Multivirus-Specific T CELLS from BOTH Cord Blood and BONE Marrow Transplant Donors (2016) (2)
- Gene Transfer of IL-7R alpha (IL-7Rα) on Antigen-Specific Cytotoxic T Cells (CTLs) Restores Their Ability To Respond to IL-7 Cytokine. (2007) (2)
- Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years (2015) (2)
- Anti-CD 40 L : biology and therapy in ITP (2)
- The clone ranger? (2008) (2)
- Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation. (2022) (2)
- Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies (2021) (2)
- Allogeneic Virus-Specific T Cells With HLA Alloreactivity Do Not Produce Graft-Versus-Host Disease in Human Subjects (2010) (2)
- Evaluating multivirus-specific T cells from both cord blood and bone marrow transplant donors: a phase 1 perspective (2014) (2)
- Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer (2022) (2)
- Multicenter Study of “off-the-Shelf” Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT) (2012) (2)
- Three-Module Signaling Endo-Domain Artifical T-Cell Receptor Which Transmits CD28, OX40 and CD3-ζ Signals Enhances IL-2 Release and Proliferative Response in Transduced Primary T-Cells. (2004) (2)
- Rapidly-Generated EBV-Specific T Cells (EBVST-cells) to Treat Type 2 Latency Lymphoma (2016) (2)
- EBV Lymphoproliferative Disease After Transplantation (2008) (2)
- Infusion of CD19-Directed and Multivirus Specific Cytotoxic T Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation for B Cell Malignancies, (2011) (2)
- T cell receptor repertoire of CD4+ and CD8+ T cell subsets in the allogeneic bone marrow transplant recipient (1995) (2)
- 1 Interleukin 15 provides relief to cytotoxic T lymphocytes from regulatory T cell-mediated inhibition : implications for adoptive T-cell based therapies of lymphoma (2012) (2)
- Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High-Risk Patients with COVID-19 (2021) (2)
- Generation Of Virus-Specific Cytotoxic T Lymphocytes (CTLS) Resistant to the Immunosuppressive Drug Tacrolimus (FK506) (2009) (2)
- Adoptive T-Cell Therapy to Prevent and Treat Human Metapneumovirus (hMPV) Infections Post Hematopoietic Stem Cell Transplant (HSCT) (2015) (2)
- Cancer Therapy : Preclinical See commentary by Rezvani , p . 6955 Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A 4 (2011) (2)
- Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma (2022) (2)
- From Tyne to Tone: a journey (1987) (1)
- Optimizing the Manufacture of CAR-T Cells for Clinical Applications (2012) (1)
- Targeting Lymphomas Using Non-Engineered, Multi-Antigen-Specific T Cells (2019) (1)
- disease: a 28-year experience in the United States Characterization and treatment of chronic active Epstein-Barr virus (2011) (1)
- Outcomes of Umbilical Cord Transplant (UCBT) Conditioned Without Serotherapy for Pediatric Malignant and Non-Malignant Diseases: Texas Children's Hospital Experience (2018) (1)
- Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting (2023) (1)
- Overcoming Antigenic Competition to Produce Multispecific Cytotoxic T Lymphocyte Lines for Adoptive Transfer (2009) (1)
- Broad Spectrum Tumor Antigen-Specific Cytotoxic T Lymphocytes (CTL) for Therapy of Hematological Malignancy. (2009) (1)
- Workshop of the Blood and Marrow Transplant Clinical Trials Network Subcommittee on Cell and Gene Therapy (2011) (1)
- Abstract IA21: Using viruses to advance T cell therapy for malignancy. (2013) (1)
- 25 The use of EBV-specific cytotoxic T lymphocytes as adjuvant therapy post stem cell transplant for relapsed EBV-positive Hodgkin disease (2003) (1)
- IMMUNOTHERAPY FOR EBV-ASSOCIATED LYMPHOPROLIFERATIVE DISEASE: S18 (1997) (1)
- Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study (2020) (1)
- 19. A Phase I Clinical Trial of Autologous HER2 CMV Bispecific CAR T Cells for Progressive Glioblastoma (2015) (1)
- Complete Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T Lymphocytes Targeting EBV Latent Membrane Proteins (2008) (1)
- LMP2-Cytotoxic T Lymphocyte Therapy for Relapsed EBV Positive Lymphoma. (2004) (1)
- Use of highly characterized EBV-Specific T Cells outside of the immediate Post-Transplant setting (2019) (1)
- Ultra low-dose IL-2 mediated expansion of regulatory T cells as GvHD prophylaxis for recipients of allogeneic hematopoietic stem cells (2012) (1)
- Adoptive T-cell Therapy for Viral Disease in the Setting of Hematopoietic Cell Transplantation (2016) (1)
- TRANSPLANTATION AND VIRUS INFECTIONS (1999) (1)
- Vaccination Strategies for Patients with B-CLL. (2008) (1)
- Rapid Generation Of Antigen-Specific T Cells for Pre-Clinical And Clinical Applications Using A Novel Mini Cell Bioreactor (2008) (1)
- A bispecific chimeric antigen receptor targeting antigen escape variants in glioblastoma (2014) (1)
- Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19 (2020) (1)
- A less sour sweet; blocking galectin. (2011) (1)
- Respiratory Viral Infections after Hematopoietic Stem Cell Transplants : The Texas Children's Hospital Experience (2016) (1)
- CMV-Specific HER2-Redirected T Cells For The Adoptive Immunotherapy Of Glioblastoma (2010) (1)
- Fourth Annual Summer Research Summit on Health Equity Organized by the Center of Excellence in Health Equity, Training and Research, Baylor College of Medicine, Houston, Texas 77030, USA on May 20, 2021 (2021) (1)
- IL15 Enhances Proliferation and Effector Function of Antigen-Specific Cytotoxic T Lymphocytes (CTLs) and Mitigates the Suppressive Action of Regulatory T Cells (Tregs). (2009) (1)
- Suicide is painless (2006) (1)
- CLIN-IMMUNOTHERAPY/BIOLOGIC THERAPIES (2012) (1)
- Commercialization of Investigational Cell Therapy Products (2021) (1)
- A PHASE I STUDY EVALUATING THE USE OF ALLODEPLETED T CELLS TRANSDUCED WITH INDUCIBLE CASPASE 9 SUICIDE GENE AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION (CASPALLO) (2009) (1)
- Options for T‐cell based therapies (2004) (1)
- Beyond CD19 CAR-T cells in lymphoma. (2021) (1)
- Application of Anti-Viral Adoptive T-Cell Therapy to Primary Immunodeficiency Patients (2013) (1)
- 87 - Use of highly characterized EBV-specific T cells for treatment of EBV+ lymphoma outside of the HSCT setting (2017) (1)
- Cytomegalovirus (CMV) infection in patients receiving either alemtuzumab (CAMPATH 1-H) or antithymocyte globulin (ATG) as graft-versus-host disease (GVHD) prophylaxis prior to allogeneic stem cell transplantation (SCT) (2004) (1)
- Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial) (2022) (1)
- CLIN-IMMUNOTHERAPY/BIOLOGIC THERAPIES (2012) (1)
- The use of autologous LMP2-specific cytotoxic T lymphocytes for the treatment of relapsed EBV+ Hodgkin’s disease and non-Hodgkin’s lymphoma (2005) (1)
- Effect of a costimulatory endodomain on the performance of T cells expressing CD19-directed chimeric antigen receptors (CARs) in subjects with relapsed/refractory B-cell malignancies. (2011) (1)
- Transduction of CD34(+) and CD34(-)/lin(-) hemopoietic progenitors by lentivirus vectors. (1999) (1)
- Immune-Based Therapies Targeting Mage-A4 for Relapsed/Refractory Hodgkin's Lymphoma After Stem Cell Transplant. (2009) (1)
- Adoptive Transfer of Multi-Tumor Antigen Specific T Cells as Treatment for Patients with Multiple Myeloma (2017) (1)
- 1074. The Use of Genetically Modified Antigen Presenting Cells to Generate Donor-Derived Virus-Specific Cytotoxic T Lymphocytes Reactive Against CMV and Adenoviral Antigens for Clinical Use (2005) (1)
- Multiple Integration Events into Several Putative Oncogenes Was Required To Cause Leukemogenesis in Two Primate Recipients of RCR Contaminated Stem-Cells. (2004) (1)
- Effect of a Co-Stimulatory Endodomain on the Performance of T Cells Expressing a Chimeric Antigen Receptor Directed at CD19 in Patients With Relapsed/Refractory B-Cell Malignancies (2011) (1)
- Matched Unrelated Allogeneic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia: Texas Children's Hospital Experience (2016) (1)
- Adoptive Transfer of Rapidly-Generated Multivirus-Specific T Cells to Treat Adenovirus, EBV and CMV Infections of Hematopoietic Stem Cell Transplant Recipients (2012) (1)
- Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies, (2011) (1)
- Flanking-Sequence Exponential Anchored (FLEA) PCR - a Sensitive and Highly Specific Method for Detecting Retroviral Integrant-Host-Junction Sequences. (2004) (1)
- Improved Homing of Antigen-Specific T Cells to Hodgkin’s Disease (HD) Tumor Cells by Forced Expression of CCR4 Receptor. (2006) (1)
- Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins (2011) (1)
- Allogeneic, Off-the-Shelf Multi-Virus Specific T-Lymphocytes for the Treatment of Virus-Associated Hemorrhagic Cystitis in the Post-HSCT Setting (2021) (1)
- 41: Long-term follow up of T cell depleted transplants from unrelated donors in pediatric patients (2007) (1)
- Current Progress in Adoptive T-Cell Therapy of Lymphoma (2012) (1)
- CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma (2022) (1)
- Commentary on journal of immunotherapy paper by melenhorst et al. (2006) (1)
- Induction of hepatic drug metabolism during high dose preparative chemotherapy for bone marrow transplantation(BMT) (1996) (1)
- Hematopoietic Stem Cell Transplantation (2003) (1)
- Comprar Hematology 7th Ed. Basic Principles and Practice | Ronald Hoffman | 9780323357623 | Elsevier Internacional (2017) (1)
- ASBMT committee report: white paper on measurement of quality outcomes. (2006) (1)
- Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant? (2022) (1)
- Evaluating Donor Lymphocyte Infusions (DLI) for the Treatment of Falling Chimerism, Minimal Residual Disease and Relapse After Pediatric Hematopoietic Stem Cell Transplantation (HSCT) (2013) (1)
- Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD (2014) (1)
- We present here a selection of written comments that were submitted by panelists who spoke at the IOM RAC workshop on August 6, 2013. (2014) (1)
- Graft Versus Leukemia Response without Graft Versus Host Disease Elicited By Adoptively Transferred Multivirus-Specific T-Cells (2014) (1)
- Adoptive Transfer of Polyclonal, EBV-Specific Cytotoxic T-Cell Lines for the Prevention and Treatment of EBV-Associated Malignancies (2000) (1)
- Multi-Tumor-Antigen-Specific Cytotoxic T Lymphocytes For Therapy Of Hematologic Malignancies (2010) (1)
- 798. Epstein Barr Virus-Specific Cytotoxic T Lymphocytes (EBV-CTL) Expressing an Anti-CD30 Chimeric T-Cell Receptor (cTcR) for the Treatment of Hodgkin's Disease (HD) (2005) (1)
- Human gene marker/therapy clinical protocols. (1996) (0)
- Incorporation of Thiotepa in a Reduced Intensity Conditioning Regimen Leads to Improved Engraftment after Stem Cell Transplant for Patients with Hemophagocytic Lymphohistiocytosis (2019) (0)
- The Clinical Use of Cord Blood-Derived Virus-Specific Cytotoxic T Lymphocytes Reactive Against Cytomegalovirus (CMV), Adenovirus, and Epstein-Barr Virus (EBV) (2006) (0)
- Adoptive immunotherapy of EBV lymphomas (1997) (0)
- Refined/Accelerated T Cell Therapies for the Treatment of EBV+ Lymphomas (2014) (0)
- Excellent Outcomes for Pediatric Non-Malignant Diseases Using Umbilical Cord Blood Transplantation (UCBT) Conditioned without Serotherapy in the Absence of a Matched Related Donor (2019) (0)
- Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Patients: A Single Institution Experience (2021) (0)
- Yuan and Su 1 highlight several important questions for addi- tional clarification and discussion. Regarding the staging of pa- tientswithnaturalkiller(NK)/T-celllymphomawithactivedisease whoweretreated,wereportthatevenpatientswithadvancedstage (2014) (0)
- Inducible Caspase 9 as a Safety Switch in Genetically Modified Cytotoxic T Cells. (2004) (0)
- 721. Safety of Multiple Doses of CAR T Cells (2015) (0)
- Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high risk patients. (2022) (0)
- Preferentially Expressed Antigen of Melanoma (PRAME)-Specific Cytotoxic T-Lymphocytes (CTLs) and Transgenic T Cells To Target Chronic Myelogenous Leukemia (CML). (2007) (0)
- Delivery of tumor-targeted immunotoxin by tumor-specific T cells (155.19) (2011) (0)
- Engineering T cells to prevent graft-versus-host disease and leukemia relapse following allogeneic stem cell transplantation (2022) (0)
- 245: Regression of Experimental Osteosarcoma and Ewing's Sarcoma following Transfer of HER2-Redirected T Cells (2008) (0)
- Outcomes in Pediatric Patients With Engraftment Failure After Allogeneic Transplants (2013) (0)
- reconstitution after haploidentical stem cell transplant Adoptive immunotherapy with allodepleted donor T-cells improves immune (2013) (0)
- Tcrb Sequencing Demonstrates Polyclonality and Persistence of Virus-Specific T-Cell Therapy (2017) (0)
- Infectious complications in reduced intensity conditioning (RIC) allogeneic stem cell transplantation with antilymphocyte antibodies. (2004) (0)
- Establishment of a Highly Characterized Third-Party Virus-Specific T Lymphocyte Bank for Treatment of EBV+ Lymphoma (2015) (0)
- 37: Cytotoxic T Lymphocytes (CTL) Specific for Multiple Viruses Can Be Generated From Umbilical Cord Blood for Adoptive Immunotherapy (2008) (0)
- Rejection-Resistant Off-the-Shelf T Cells for Adoptive Cell Therapy (2019) (0)
- Phase I Trial of GD2.CAR T Cells Combined with a Novel Interleukin-7 Signal Modulator (2022) (0)
- Treatment of High-Risk Neuroblastoma with Adoptively Transferred T Lymphocytes Genetically Engineered to Recognize GD2 (2009) (0)
- Multivirus-Specific T Cell Immunotherapy To Prevent Or Treat Infections Of Allogeneic Stem Cell Transplant Recipients (2009) (0)
- Reconstitution of the T cell receptor alpha beta repertoire in recipients of allogeneic BMT. (1992) (0)
- 71: Virus-specific T cells engineered to co-express tumor-specific receptors; effects in patients with neuroblastoma (2007) (0)
- Deferred Dosing of Granulocyte Colony Stimulating Factors in Autologous Hematopoietic Transplantation for Multiple Myeloma (2013) (0)
- Genetic Modification of Antigen-Specific Cytotoxic T Lymphocytes (CTLS) Restores Their Ability to Respond to Interleukin-7 (IL-7) (2009) (0)
- Contents, Vol. 83, 1990 (1990) (0)
- The Use of Donor Lymphocyte Infusions As Prophylaxis and Treatment for Relapse in Children Post Hematopoietic Cell Transplant for Malignant Disease: A Single Institution Experience (2017) (0)
- Activation of LMP1- and LMP2-specific T-cells for the immunotherapy of EBV positive malignancies with an adenoviral vector encoding full length LMP1 and LMP2 (2006) (0)
- Cord Blood Transplant for Very High Risk Hematologic Malignancies in Children Using Conditioning Without Serotherapy (2018) (0)
- Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV-6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant (2016) (0)
- Evaluation of reduced intensity allogeneic hematopoietic stem cell transplantation (HSCT) using anti lymphocyte antibodies in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). (2004) (0)
- Chapter 103 – Overview and Choice of Donor of Hematopoietic Stem Cell Transplantation (2017) (0)
- Graft-versus-Host Disease : The Pesky Fly in the Ointment (2007) (0)
- Health disparities experienced by Black Americans with multiple myeloma in the United States: A population-based study. (2021) (0)
- 188: Single Institution's Outcomes for First Transplant as Salvage Therapy for Hodgkin's Lymphoma (2008) (0)
- Virus-Specific T Cells for the Treatment of Malignancies—Then, Now, and the Future (2020) (0)
- Human gene marker/therapy clinical protocols. (1999) (0)
- 766. Immunotherapy for Her2-Positive Medulloblastoma: Regression of Experimental Tumors by Transfer of Her2-Redirected T Cells In Vivo (2006) (0)
- Safety and Persistence of Infused CD19-Car-Modified Multivirus Specific CTLs in B Cell Malignancies Post Allogeneic Hematopoietic Stem Cell Transplantation (2012) (0)
- Engineering haploidentical transplants (2015) (0)
- omparable Outcomes of Matched-Related and lternative Donor Stem Cell Transplantation or Pediatric Severe Aplastic Anemia (2006) (0)
- Suicide Caspase 9 Gene For Improved Safety Of Therapies Using Mesenchymal Stromal Cells (2010) (0)
- Portal venous Doppler findings in a bone marrow transplant patient with cardiac tamponade. (1995) (0)
- EBV PTLD: Diagnosis and Management (2008) (0)
- Transplantation in children Energy expenditure in children undergoing hematopoietic stem cell transplantation (2002) (0)
- 221: A submyeloablative regimen of Campath-1H and Fludarabine for patients with graft failure following allogeneic transplantation from MHC identical or near identical donors (2007) (0)
- A phase Iclinical trial ofrecombinant interleukin 2following highdose chemo-radiotherapy forhaematological malignancy: applicability tothe elimination ofminimal residual disease (1989) (0)
- Human Papillomavirus Type 16 (HPV16) E6/E7-Specific Cytotoxic T Lymphocytes (CTLs) for Immunotherapy of HPV-Associated Malignancies (2011) (0)
- To T-cell deplete or not (2005) (0)
- Gene therapy. (2007) (0)
- Outcomes after Allogeneic Stem Cell Transplantation for Patients with Non-Hodgkin Lymphoma: Texas Children's Hospital Experience 1999-2013 (2015) (0)
- T Cells Expressing CD19-Specific Chimeric Antigen Receptors Are Inhibited By Indoleamine 2,3-Dioxygenase in Tumors (2014) (0)
- HL-210: Assessment and Reporting of Quality of Life Measures in Pivotal Clinical Trials of Lymphoma (2020) (0)
- Outcomes After Second Allogeneic Transplants in Pediatric Patients With Relapsed Hematological Malignancies (2013) (0)
- Phase I clinical trial of recombinant IL2 following chemoradiotherapy (1989) (0)
- Optimized manufacturing process for the generation of clinical grade CAR T cells (2015) (0)
- Outcome after Allogeneic Stem Cell Transplant for Patients with Hematological Malignancies and Associated Chromosome 7 Deletions (2014) (0)
- Autologous hematopoietic stem cell transplantation with a rituximab-containing preparative regimen for non-Hodgkin lymphoma (2007) (0)
- Editorial on HIT series on emergent CAR T-cell toxicities. (2023) (0)
- Outcome of alternative donor transplantation for severe aplastic anemia can be comparable to outcome with matched related donors (2006) (0)
- Chronic GvHD Incidence and Outcome: Single Center Experience (2017) (0)
- Abstract 3501: Binary control of CAR-CTL by transgenic IL-7 and IL-7R expression (2012) (0)
- Go-CART: an animal-free system for the assessment of CAR T cell function (2015) (0)
- nducible Caspase 9 Suicide Gene to Improve the afety of Allodepleted T Cells after Haploidentical tem Cell Transplantation (2007) (0)
- Excellent Engraftment with Reduced Treatment Related Mortality for Young Pediatric Patients Using Umbilical Cord Blood Transplantation (UCBT) Conditioned without Serotherapy (2020) (0)
- An Optimized Process of Generating CAR-T Cells for Clinical Applications (2016) (0)
- Outcomes after Matched Unrelated Donor Stem Cell Transplantation in Chronic Granulomatous Disease – an Update (2016) (0)
- Outcomes of myeloablative, T cell deplete unrelated donor hematopoietic stem cell transplantation at a single center. (2020) (0)
- Umbilical Cord Blood Transplantation Can be an Effective Therapy for Patients with Primary Immunodeficiency Diseases Who Lack an HLA-Matched Related Donor (2014) (0)
- Allogeneic bone marrow transplantation at Christchurch 1979-1985. (1986) (0)
- C-10. Inducible Caspase-9 Suicide Gene Controls Adverse Effects from Alloreplete T Cells after Haploidentical Stem Cell Transplantation (2015) (0)
- 1 CrosstalkbetweentumorCellsandendotheliumreCruitst lymphoCytestothetumormiCroenvironment enhanCing tumor growth in vivo (0)
- MYELODYSPLASTIC SYNDROME (2005) (0)
- Engineering CD19-Redirected T Lymphocytes to Enhance Their Safety and Efficacy (2008) (0)
- Transplantation from Matched Unrelated Donors (MUD) for Thalassemia and Other Congenital Red Cell Disorders. (2005) (0)
- Rasburicase Improves Renal Function and Uric Acid Nephropathy in Patients Developing Acute Renal Failure after Conditioning for Hematopoetic Stem Cell Transplant (HSCT). (2004) (0)
- 751. Improving CAR T Cell Function by Reversing the Immunosuppressive Tumor Environment of Pancreatic Cancer (2016) (0)
- A “non-fratricidal” αβ- T Cell Receptor That Targets Survivin Expressed By Hematological Malignancies (2013) (0)
- The 2007 Educational Supplement on Hemopoetic Cell Transplantation (2007) (0)
- Immunotherapy with Antigen Specific T Cells (2015) (0)
- Poster session IIGVH/GVL304: Rituximab responsive refractory acute graft versus host disease (2007) (0)
- Matched Unrelated Allogeneic Stem Cell Transplantation for Patients with Congenital Amegakaryocytic Thrombocytopenia: Texas Children`s Hospital Experience (2015) (0)
- Guidance for developing phase II cell therapy trial proposals for consideration by the Blood and Marrow Transplant Clinical Trials Network. (2011) (0)
- Adoptive Transfer of HER2-Specific T Cells Eradicates Experimental Glioblastoma Multiforme (2009) (0)
- Main Session III (2002) (0)
- New Guidelines Help Health Professionals Recognize and Manage Late Complications (2006) (0)
- T Cell Therapy for Multiple Myeloma (2016) (0)
- Safety and Clinical Efficacy of Rapidly-Generated Trivirus-Directed T Cells After Allogeneic Hematopoietic Stem Cell Transplant (2012) (0)
- Epstein Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL) Expressing an Anti-CD30 Chimeric T Cell Receptor (CTCR) for the Treatment of Hodgkin’s Disease (HD). (2004) (0)
- IVIG Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant: A Retrospective Analysis of Monthly Intravenous Immunoglobulin Infusion vs. IgG Level Based Dosing (2016) (0)
- Response of steroid-resistant GvHD to lymphoblast antibody CBL1 (1995) (0)
- Longitudinal Dynamics of Clonal Hematopoiesis in Patients Receiving Anti-CD30 CAR T-Cell Therapy (2023) (0)
- Safety and Tolerability of Administering Leukemia-Specific Donor T Cells (mLSTs) after Allogeneic Transplant to Pediatric Patients with AML/MDS (2022) (0)
- GD2.CAR T Cells Incorporating a Constitutively Active Interleukin-7 Signal Modulator for CNS Tumors (2023) (0)
- Treatment of Epstein-Barr virus-associated lymphomas: the role of Epstein-Barr virus-specific cytotoxic T cells (2009) (0)
- Abstract A44: Minority enrollment to clinical trials: Experience at the Dan L. Duncan Cancer Center (2010) (0)
- Extending the Option of CMV-Specific T Cells from the CMV-Seronegative Donor (2014) (0)
- Post-transplant complications Guillain-Barresyndrome after allogeneic hematopoietic stem cell transplantation (2002) (0)
- Immunotherapy for HER2-positive medulloblastoma: Regression of experimental tumors by transfer of HER2-redirected T cells in vivo. (2016) (0)
- HIGH GRADE GLIOMAS AND DIPG (2014) (0)
- INTRODUCTION TO A REVEW SERIES ON BANKED ALLOGENEIC IMMUNE EFFECTOR CELLS. (2023) (0)
- Adoptive cellular and gene therapy (2012) (0)
- PEPTIDE VACCINE THERAPY FOR CHILDHOOD GLIOMAS : UPDATED RESULTS OF A PILOT STUDY (2012) (0)
- Lymphoma EBV-Positive Nasopharyngeal Carcinoma and Specificity in CTL Lines from Patients with Characterization of Latent Membrane Protein 2 (2011) (0)
- The Graying of Clinical Transplantation (2006) (0)
- 190. Adaptive CAR T Cell Design (2016) (0)
- Mixed Donor Chimerism after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome (2015) (0)
- 60 Adenovirus infection (A1) and disease (AD) in pediatric matched unrelated donor bone marrow transplant (BMT) patients receiving either anti-thymocyte globulin (ATG) or campath during conditioning (2003) (0)
- Reduced Autoimmune Cytopenias after Cord Blood Transplant in Pediatric Patients with Nonmalignant Disease Conditioned without Serotherapy (2020) (0)
- Umbilical Cord Blood Transplantation Conditioned without Serotherapy Is an Excellent Curative Alternative for Pediatric Non-Malignant Diseases (2015) (0)
- Cytotoxic T Lymphocytes (CTL) Specific For CMV, Adenovirus, And EBV Can Be Generated From Naive T Cells For Adoptive Immunotherapy (2010) (0)
- Erratum: CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo (Science Translational Medicine (2016) 8:321 (321er1)) (2016) (0)
- Genetically Modified Her2-Specific T Cells Recognize Low and High Her2 Expressing Breast Cancer Cells. (2005) (0)
- Administration of Banked, 3rd Party Multivirus-Specific T Cells to Treat Drug-Refractory EBV, CMV, AdV, HHV6, and BKV Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients (2017) (0)
- Excellent Survival After Stem Cell Transplantation for non-SCID Primary Immunodeficiencies (2011) (0)
- Go-Rex: A Novel in Vitro System for the Assessment of CAR T Cell Function (2016) (0)
- #413 CTL Therapy for post-transplant lymphoproliferative disease and relapsed Hodgkin's disease (1997) (0)
- Human papillomavirus type 16 (HPV16) E6/E7-specific cytotoxic T lymphocytes (CTL) for immunotherapy of HPV-associated cancer (Ca). (2012) (0)
- Combined Epigenetic and Immune-Based Therapies for Relapsed Hodgkin'S Lymphoma Post Hematopoietic Stem Cell Transplant (2011) (0)
- Human gene marker/therapy clinical protocols. (2000) (0)
- Dimerize and die (2004) (0)
- Cellular therapies for lymphoma (2010) (0)
- Immunotherapy for Virus-Associated Malignancies (2002) (0)
- [Contribution of antineoplastic biotherapy in the treatment of leukemia in children]. (2002) (0)
- Virus-Specific T Cells for the Treatment of Malignancies—Then, Now, and the Future (2020) (0)
- Stem Cell Transplant for HLH: Single Institution Series (2011) (0)
- A Phase II study of carboplatin and docetaxel followed by epstein-barr virus specific cytotoxic T Lymphocytes for refractory/relapsed EBV-positive nasopharyngeal carcinoma (2013) (0)
- malignancies antigen for the adoptive immunotherapy of EBV-associated Generating CTLs against the subdominant Epstein-Barr virus LMP1 (2013) (0)
- Transgenic Expression of IL15 Selectively Expands Antigen Specific Cytotoxic T Cells (CTLs) Enhancing Their Anti-Tumor Effect In Vivo. (2006) (0)
- Immune Reconstitution in Children Receiving Cord Blood Transplantation (CBT) Without the Use of Lymphocytolytic Antibodies (2012) (0)
- Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION) (2022) (0)
- High efficiency gene transfer to normal and malignant hematopoietic precursor cells using a chimeric adenovirus (2000) (0)
- infusion of T cells expressing the inducible caspase 9 safety transgene Long-term outcome after haploidentical stem cell transplant and (2014) (0)
- Immediate Adverse Events Following infusion of ex vivo-Expanded Cord Blood for Stem Cell Transplantation (2011) (0)
- PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY (2010) (0)
- Reply to S. Yuan et al. (2014) (0)
- Virus-specific T cells as treatment for nasopharyngeal carcinoma. Comment (2005) (0)
- Improving Immunotherapy Targeted at Subdominant Tumor Antigens (2005) (0)
- Retrovirus-Transduced T Cell Blasts Have Not Only Antigen-Presenting Capabilities but Also Suppressor Regulatory T Cell-Inducing Capability. (2004) (0)
- Adoptively-Transferred Epstein-Barr Virus (EBV)-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipients - a Single Center Experience Spanning 22 Years (2016) (0)
- Infusion of CD19-directed/multivirus specific-cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation for B cell malignancies (2013) (0)
- Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. (2021) (0)
- Haploidentical Hematopoietic Stem Cell Transplantation with CD34 Positive Selection in Children with Hematological Malignancy- a Single Center Experience of 16 Years (2017) (0)
- 203Allogeneic bone marrow transplantation for children with myeloid hematologic malignancies (2003) (0)
- Gene therapy of pediatric leukemia. (2000) (0)
- Outcome after Stem Cell Transplant in Patients with Dyskeratosis Congenita (2014) (0)
- CMVpp65-Specific T Cells Generated from Naïve T Cell Populations Recognize Atypical but Not Canonical Epitopes and May Be Protective In Vivo (2015) (0)
- Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL (2021) (0)
- Polyclonal Prame-Specific Cytotoxic T Lymphocytes Generated Using Protein-Spanning Pools of Overlapping Pentadecapeptides Target Chronic Myeloid Leukemia (2008) (0)
- Genomic Characterization of a Pediatric Cohort with Non-Malignant Lymphoproliferative Disorders (2019) (0)
- Whole genome sequencing of sporadic Burkitt lymphoma in HIV-infected and uninfected patients. (2013) (0)
- Induction of Preferentially Expressed Antigen of Melanoma (Prame)-Specific Immunity by Prame-Overlapping Pentadecapeptides in Patients With Hematologic Malignancies, Including Chronic Myelogenenous Leu (2009) (0)
- 513. Establishment of a Highly Characterized Third-Party Virus-Specific T Lymphocyte Bank for Treatment of EBV+ Lymphoma (2015) (0)
- A ″Non-Fratricidal″ αβ-T Cell Receptor That Targets Survivin Expressed By Hematological Malignancies (2014) (0)
- Abstract P3-05-07: Improving CAR T cell function by reversing the immunosuppressive tumor environment of breast cancer (2018) (0)
- Cytotoxic T Lymphocytes (CTL) Specific for Adenovirus and CMV Can Be Generated from Umbilical Cord Blood for Adoptive Immunotherapy (2008) (0)
- disease Prompt versus preemptive intervention for EBV lymphoproliferative (2013) (0)
- Adverse Events Following Infusion of T Cells for Adoptive Immunotherapy: A 10 Year Experience. (2009) (0)
- The Clinical Use of Donor-Derived Virus-Specific Cytotoxic T Lymphocytes Reactive Against Cytomegalovirus (CMV), Adenovirus and Epstein Barr Virus (EBV). (2005) (0)
- Invasive Fungal Infections after Hematopoietic Stem Cell Tranplant Recipients : Texas Children's Hospital Experience (2016) (0)
- Cytotoxic T Lymphocytes (CTL) Specific for CMV, Adenovirus, and EBV Can Be Generated From Naive T Cells for Adoptive Immunotherapy. (2009) (0)
- Abstract IA22: Immunotherapy with virus-specific T cells (2016) (0)
- The Impact of Donor Baseline Characteristics on Total Nucleated Cell Count in Marrow Products of Healthy Bone Marrow Donors (2019) (0)
- Cytopenia after Cell Therapy and Lymphodepletion in Patients with Leukemia, Lymphoma, and Solid Tumors (2021) (0)
- CHAPTER 42 – Viral infections (2009) (0)
- Multivirus-Specific CTl for Adoptive Transfer Using in Vitro Pepmix Stimulation (2011) (0)
- Treatment of Epstein Barr-positive nasopharyngeal carcinoma with adoptively transferred cytotoxic T cells (2006) (0)
- or antileukemic responses Selective depletion of donor alloreactive T cells without loss of antiviral (2013) (0)
- New Strategies for Fungal Infections after Hematopoietic Cell Transplantation : Prevention or Preemption ? (2007) (0)
- emolytic Uremic Syndrome after Bone Marrow ransplantation : Clinical Characteristics and Outcome n Children (2005) (0)
- Severe mononucleosis in a girl with progression to lymphoma–Epstein Barr Virus (EBV)-associated lymphoproliferative disease (LPD) that mimics X-linked lymphoproliferative disease (XLPD) (2005) (0)
- This information is current as Carcinoma and Lymphoma Patients with EBV-Positive Nasopharyngeal Protein 2 Specificity in CTL Lines from Characterization of Latent Membrane (2017) (0)
- Subject Index, Vol. 83, 1990 (1990) (0)
- Gene Transfer into Hemopoietic Progenitors: Implications for Bone Marrow Transplantation (1996) (0)
- Graft-versus-yogurt (2004) (0)
- Stem Cell Transplantation and Long-Term Survival for Primary Immunodeficiencies: Outcomes Among the Donor Sources and Different Diagnostic Groups (2013) (0)
- TCR expression; quantitative easing by CD3. (2011) (0)
- Secreted Fas decoys enhance the antitumor activity of engineered and bystander T cells in Fas ligand-expressing solid tumors. (2022) (0)
- T Cells from Virus Naive Individuals Cytotoxic + Generation of EBV-Specific CD 4 and (2001) (0)
- 722. Overcoming EBV Tumor Specific T-Cell Anergy in Rapidly-Generated EBVST-Cells for Adoptive Transfer Therapy (2015) (0)
- Umbilical Cord Transplant (UCBT) Without Serotherapy for Malignant and Non Malignant Diseases Provides a Curative Alternative with Improved Immune Reconstitution (2017) (0)
- Adoptive Immunotherapy with Memory T Cells. (2008) (0)
- T Cell Immunotherapy for Adenoviral Infections of Stem Cell Transplant Recipients. (2006) (0)
- 252: Outcome of allogeneic hematopoietic stem cell transplantation for pediatric patients with chronic myeloid leukemia (2007) (0)
- Chapter 94 – Overview and Historical Perspective of Current Cell-Based Therapies (2018) (0)
- Use of safety modified retroviruses to improve the outcome of bone marrow transplantation (1995) (0)
- Outcome of Alternative Donor Transplantation for Severe Aplastic Anemia Can Be Comparable to Outcome with Matched Related Donors. (2005) (0)
- Assessing cytomegalovirus (CMV) specific immune recovery after reduced intensity conditioning allogeneic stem cell transplantation with monoclonal antibody (Alemtuzumab) (2005) (0)
- Gene making after bone marrow transplantation (1994) (0)
- Efficacy of Letermovir for CMV Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplant T-Cell Depleted with Alemtuzumab (2021) (0)
- T-Cell Therapies for EBV-Associated Malignancies (2005) (0)
- Genetic and Mechanistic Diversity in Hemophagocytic Lymphohistiocytosis (2018) (0)
- Consulting or Advisory Role: Cellmedica (I) Research Funding: Celgene (Inst) Patents, Royalties, Other Intellectual Property: Cell Medica (I) (2014) (0)
- B Cell Engraftment in SCID Patients After Stem Cell Transplantation (2013) (0)
- Engineered off-the-shelf therapeutic T cells resist host immune rejection (2020) (0)
- Bi-Specific T Cell Therapy for Pancreatic Cancer (2013) (0)
- Genetic modulation of effector cells to enhance GVL effects (2000) (0)
- An antigen presenting complex for the generation of broad-specificity effector T lymphocytes for the treatment of EBV-associated malignancies (2013) (0)
- Abstract B17: Banked Epstein-Barr virus specific T-cells for treatment of EBV+ lymphoma (2015) (0)
- Production of Mage-A4-Specific CTL from Healthy Donors, Patients, and Cord Blood for Lymphoma Therapy After Transplant (2009) (0)
- Tumor immunity and immunosurveillance (PP-093) (2010) (0)
- Excellent Outcomes for Pediatric and Adult Patients with Hodgkin Lymphoma Receiving Rituximab As Adjunctive Therapy to BEAM Conditioning for Autologous Stem Cell Transplantation (2021) (0)
- Long-Term Organ Function in Children Following Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (2016) (0)
- Expansion Of Regulatory T Cells With Ultra Low-Dose Il-2 After Allogeneic Hematopoietic Stem Cell Transplantation (2009) (0)
- Abstract B8: Adoptive immunotherapy targeting tumor heterogeneity in high-grade glioma (HGG) (2014) (0)
- 207Allogeneic bone marrow transplantation for children with hematologic malignancies (2003) (0)
- Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells (2018) (0)
- Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial) (2022) (0)
- for the adoptive Immunotherapy of EBV-associated malignancies Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen (2013) (0)
- Chimeric Antigen Receptor Gene-Modified Virus-Specific T-Cell Expanded in Patients with Reactivated Epstein-Barr Virus Post Allogeneic Stem Cell Transplant (2016) (0)
- Running title: T cell therapy for EBV+ nasopharyngeal carcinoma (2004) (0)
- NaïVe T Cells From Cord Blood and CMV-Seronegative Donors Recognize Atypical Epitopes of Cmvpp65 and Can Be Used for Adoptive Immunotherapy (2011) (0)
- The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies (2010) (0)
- Expansion of Lymphocytes for Cell-Based Therapeutics (2010) (0)
- Safely Improving the in Vivo Survival of Tumor Specific Cytotoxic T Lymphocytes by Co-Transfer of IL7 Receptor Alpha Chain and icaspase9 (2008) (0)
- Abstract B63: Improving CAR T cell function by reversing the immunosuppressive tumor environment of pancreatic cancer (2015) (0)
- Reconstitution of immunity to adenovirus (Ad) after pediatric bone marrow transplant (2005) (0)
- 518. Artificial Mouse Model: An Animal-Free System for Assessment of CAR-T Cell Function (2015) (0)
- 278: Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation (2007) (0)
- Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor Associated Antigens (2018) (0)
- Allogeneic Stem Cell Transplantation for Chronic Active EBV infection (CAEBV) (2011) (0)
- Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy (2023) (0)
- Multivirus-Specific T Cell Immunotherapy to Prevent or Treat Infections of Stem Cell Transplant Recipients. (2008) (0)
- High Incidence but Low Morbitiy of Early Cytomegalovirus (CMV) Infections Following Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation with Alemtuzumab and Ganciclovir Prophylaxis. (2004) (0)
- Chapter 4 The Generation and Characterization of LMP 2-specific CTLs for Use As Adoptive Transfer From Patients with Relapsed EBV-Positive Hodgkin Disease (2006) (0)
- CTLs lymphoproliferative disease unresponsive to therapy with virus-specific An Epstein-Barr virus deletion mutant associated with fatal (2013) (0)
- Monoculture-Derived Leukemia and Multivirus Specific Cytotoxic T-Lymphocytes for Immunotherapy of All in Hematopoietic Stem Cell and Umbilical Cord Blood Transplants (2009) (0)
- 451. Robust Manufacture of CAR-T Cells (2016) (0)
- Binary Control of Tumor-Specific Cytotoxic T Lymphocytes by Transgenic IL7 and IL7 Receptor Expression (2011) (0)
- Adoptive Immunotherapy to Prevent and Treat HHV-6 Reactivation Post Allogenic Stem Cell Transplant (2011) (0)
- Expansion of T Cells Targeting Multiple Antigens of CMV, EBV, and Adenovirus to Provide Broad Antiviral Specificity After Stem Cell Transplantation (2011) (0)
- Paving the Road for CAR-Ts: ASTCT 80/20 Task Force consensus on challenges and solutions to improving efficiency of clinical center certification and maintenance of operations for commercially approved immune effector cell therapies. (2023) (0)
- Successful treatment of 2 patients with B-cell post-transplant lymphoproliferative disorders with rituximab (2000) (0)
- Evaluating the Safety and Clinical Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma (2022) (0)
- Long term follow up of subsequent malignancies in patients treated with genetically modified immune effectors (2021) (0)
- 223: Alternative Donor Hematopoietic Stem Cell Transplantation for Pediatric Patients with Acute Lymphoblastic Leukemia Using Campath in a Myeloablative Conditioning Regimen (2008) (0)
- 81: Enhancing the in vivo expansion of adoptively transferred EBV-CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients (2007) (0)
- Tumor-intrinsic causes of CAR-T failure. (2022) (0)
- Long Term Follow up for the Development of Subsequent Malignancies in Patients Treated with Genetically Modified Immune Effectors (2022) (0)
- Abstract LB-199: A rationally designed bispecific chimeric antigen receptor molecule that simultaneously redirects T cells to target HER2 and GD2 in osteosarcoma (2014) (0)
- Administration of T cells targeting tumor associated antigens to patients with myeloma (2017) (0)
- The clinical use of cord blood-derived virus-specific cytotoxic T lymphocytes reactive against Cytomegalovirus, Adenovirus, and Epstein-Barr Virus (105.50) (2011) (0)
- Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies (2023) (0)
- Abstract P3-06-04: Treatment of Metastatic Breast Cancer with Multipotent Oncolytic/Helper Adenovirus CAdVEC (2023) (0)
- Homeostatic action of interleukin-4 on endogenous and recombinant interleukin-2-induced activated killer cell function (1991) (0)
- Cytotoxic T Lymphocytes (CTL) specific for CMV, adenovirus, and EBV can be generated from naive T cells for adoptive immunotherapy (145.22) (2010) (0)
- Transgenic Expression of Inducible Caspase9 Suicide Gene for In Vivo Elimination of Antigen Specific Cytotoxic T Cells (CTLs) Engineered To Produce Cytokines. (2006) (0)
- Review Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells (2005) (0)
- Increasing the purity, potency and specificity of ebv-specific T cells to improve the treatment of EBV-positive lymphoma (2015) (0)
- Epstein Barr Virus-Specific T-cells grafted with Minor Histocompatibility Antigen HA-1 Specificity by Retroviral T-cell Receptor Transfer (2006) (0)
- Adoptive transfer of rapidly-generated multivirus-specific T cells to treat Adv, EBV, CMV, BK and HHV6 infections of HSCT recipients (2013) (0)
- Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. (2022) (0)
This paper list is powered by the following services:
Other Resources About Helen Heslop
What Schools Are Affiliated With Helen Heslop?
Helen Heslop is affiliated with the following schools:
